RNS Number : 2025C MaxCyte, Inc. 21 February 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Consolidation of Trading Lines Total voting rights Gaithersburg, Maryland - 21 February 2022: MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform
GAITHERSBURG, Md., Feb. 14, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
RNS Number : 5088B MaxCyte, Inc. 14 February 2022 MaxCyte to Participate in Upcoming Investor Conferences GAITHERSBURG, MD , February 14, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell - engineering company focused on providing enabling platform technologies
RNS Number : 5087B MaxCyte, Inc. 14 February 2022 MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GAITHERSBURG, MD , February 14, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform
GAITHERSBURG, Md., Feb. 11, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery,
Intima Bioscience to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to accelerate the development of its solid tumor cell-therapy candidates NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of
RNS Number : 2329A MaxCyte, Inc. 01 February 2022 MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs Intima Bioscience to use
Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.7 million Installed base of greater than 500 instruments 15 SPLs, covering more than 95 programs, of which over 15% have entered the clinic Precommercial milestone revenue
RNS Number : 3037Z MaxCyte, Inc. 24 January 2022 MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results · Fourth quarter 2021 revenue expected to be greater than $10 million · Full year 2021 revenue expected to be greater than $33.7
RNS Number : 9767W MaxCyte, Inc. 29 December 2021 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
